TRANDOLAPRILAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H30N2O5
Molecular Weight	402.484
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)[C@@]1([H])CCCC2)C(O)=O

InChI

InChIKey=AHYHTSYNOHNUSH-HXFGRODQSA-N

InChI=1S/C22H30N2O5/c1-14(23-17(21(26)27)12-11-15-7-3-2-4-8-15)20(25)24-18-10-6-5-9-16(18)13-19(24)22(28)29/h2-4,7-8,14,16-19,23H,5-6,9-13H2,1H3,(H,26,27)(H,28,29)/t14-,16+,17-,18-,19-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00519
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020528s024lbl.pdf

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Trandolapril is marketed by Abbott Laboratories under the brand name Mavik.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 96 Target ID: CHEMBL1808 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020528s024lbl.pdf \| http://www.drugbank.ca/drugs/DB00519	Inhibitor 8146		15.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 546 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020528s024lbl.pdf	Primary		Approved 8307	MAVIK Approved Use Hypertension MAVIK is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction MAVIK is indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Launch Date 8.303904E11
Heart failure post myocardial infarction 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020528s024lbl.pdf	Primary		Approved 8307	MAVIK Approved Use Hypertension MAVIK is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction MAVIK is indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Launch Date 8.303904E11

C_max

Value	Dose	Analyte	Population
9 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TRANDOLAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.99 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TRANDOLAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.3 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TRANDOLAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TRANDOLAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
101 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TRANDOLAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
19.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TRANDOLAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TRANDOLAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.2 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TRANDOLAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
115 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANDOLAPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANDOLAPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/	unhealthy, 55 n = 151 Health Status: unhealthy Condition: hypertension Age Group: 55 Sex: M+F Population Size: 151 Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/	Disc. AE: Diarrhea, Dizziness... AEs leading to discontinuation/dose reduction: Diarrhea Dizziness Elevated liver enzymes Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/

AEs

AE	Significance	Dose	Population
Diarrhea	Disc. AE	8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/	unhealthy, 55 n = 151 Health Status: unhealthy Condition: hypertension Age Group: 55 Sex: M+F Population Size: 151 Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/
Dizziness	Disc. AE	8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/	unhealthy, 55 n = 151 Health Status: unhealthy Condition: hypertension Age Group: 55 Sex: M+F Population Size: 151 Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/
Elevated liver enzymes	Disc. AE	8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/	unhealthy, 55 n = 151 Health Status: unhealthy Condition: hypertension Age Group: 55 Sex: M+F Population Size: 151 Sources: https://pubmed.ncbi.nlm.nih.gov/9231890/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CES1 22 CES2 24

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CES2 24	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/24141856/	no	TRANDOLAPRIL 3
CES1 22	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/24141856/	yes [Km 1721 uM]	TRANDOLAPRIL 3

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-1477	http://www.3bsc.com/index/pro_info.php?id=55193
Alfa Chemistry	AP87679718	https://reagents.alfa-chemistry.com/product/trandolapril-related-compound-e-cas-87679-71-8-17686.html
Alfa Chemistry	83601-86-9	https://www.alfa-chemistry.com/cas_83601-86-9.htm
BLD Pharm	BD154453	http://www.bldpharm.com/products/87679-71-8.html
ChemMol	49422350	http://www.chemmol.com/chemmol/49422350.html
Clearsynth	CS-O-08347	https://www.clearsynth.com/en/CSO08347.html
DC Chemicals	DC32672	http://www.dcchemicals.com//product_show-Trandolaprilat.html
Excenen	EX-A4862	https://www.excenen.com/searchresultlist.php?id=EX-A4862
Glentham Life Sciences	GP7119	http://www.glentham.com/products/product/GP7119/
MuseChem	R044833	https://www.musechem.com/product/R044833.html
OChem	21859	http://www.ocheminc.com/index.php?act=psearch&pid=679T718
Smolecule	S545706	http://www.smolecule.com/products/s545706
THE BioTek	bt-286404	https://www.thebiotek.com/product/inhibitors/bt-286404
eNovation Chemicals	D591705	https://www.enovationchem.com/ProductDetails.asp?ProductID=D591705
iChemical	EBD21706	http://www.ichemical.com/products/87679-71-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor.	1992 Oct 29	1414922
High-dose verapamil + trandolapril-induced thrombotic microangiopathy.	2002	12611489
[Clinical sequelae of tissue angiotensin converting enzyme inhibition: practicability of use in ischemic heart disease].	2002	12494137
Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. quinapril.	2002 Dec	12685514
Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension.	2002 Nov	12484506
Effect of endothelin blockade on early cardiovascular remodeling in the one-clip-two-kidney hypertension of the rat.	2003	14610336
Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat.	2003 Apr	12670751
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.	2003 Aug	12865039
The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function.	2003 Dec	14643272
ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established.	2003 Dec	14633150
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.	2003 Dec 3	14657064
Exercise testing in hypertensive patients taking different angiotensin-converting enzyme inhibitors.	2003 Feb	12640507
Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study.	2003 Jan	12669106
Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models.	2003 Jan	12480961
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.	2003 Jan 11	12531578
ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.	2003 Jul	12831343
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study.	2003 Jul	12830458
Choosing a drug from within a class.	2003 Jun	12833771
ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.	2003 Jun	12802493
Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.	2003 Jun	12783115
Tick-borne encephalitis with hemorrhagic syndrome, Novosibirsk region, Russia, 1999.	2003 Jun	12781020
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.	2003 Jun 1	12798439
Role of L-type calcium channels in pacing-induced short-term and long-term cardiac memory in canine heart.	2003 Jun 10	12756152
[The effect of analysed hypotensive drugs on certain metabolic parameters].	2003 Mar	12924169
Trandolapril: a newer angiotensin-converting enzyme inhibitor.	2003 Mar	12852701
Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure.	2003 Mar	12618236
The COOPERATE trial.	2003 Mar 22	12660076
The COOPERATE trial.	2003 Mar 22	12660075
A study on the stereochemical purity of trandolapril and octahydro-1H-indole-2-carboxylic acid by HPLC method.	2003 Mar-Apr	13678325
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.	2003 May	12745200
Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes.	2003 May	12736518
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.	2003 Nov	14714578
Submaximal dose of trandolapril in the COOPERATE trial?	2003 Nov	14531832
Aldosterone antagonism and myocardial infarction: from animals to man and back.	2003 Nov 5	14607458
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.	2003 Nov 5	14607457
Some recent randomized clinical trials in the management of atrial fibrillation.	2003 Oct	14574035
Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients.	2003 Oct 14	14557351
Verapamil reverts acute renal functional impairment induced by angiotensin II converting enzyme inhibitors.	2003 Sep	14575281
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.	2003 Sep	13679434
[Induction of heat shock protein 70 in failing heart].	2004 Feb	14745126
ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes.	2004 Feb	14727024
[Preventive therapy with ACE inhibitors for coronary patients].	2004 Feb 29	15077477
Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients.	2004 Jan	15055251
Effect of nolomirole on monocrotaline-induced heart failure.	2004 Jan	14597145
Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors.	2004 Mar	15080380
[Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation].	2004 Mar	15049134
Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism.	2004 Mar 1	14984722
[Diagnosis of and therapy for renal hypertension].	2004 Mar 10	15052808
[Therapeutic strategy for patients with stable-stage chronic kidney failure].	2004 Mar 10	15052806
Pharmacological treatment and prevention of heart failure in the diabetic patient.	2004 Winter	15029109

Patents

Sample Use Guides

In Vivo Use Guide

The recommended initial dosage of MAVIK (Trandolapril) for patients not receiving a diuretic is 1 mg once daily in non-black patients and 2 mg in black patients.

Route of Administration: Oral

In Vitro Use Guide

Trandolapril at 10(-7) mol/l, significantly increased 11beta-HSD2 activity after pretreatment for 16 or 24 h of the human epithelial colon cell line SW-620

Name

Type

Language

TRANDOLAPRILAT

Official Name

English

TRANDOLAPRIL IMPURITY E [EP IMPURITY]

Common Name

English

TRANDOLAPRIL DIACID

Common Name

English

RU-44403

Code

English

trandolaprilat [INN]

Common Name

English

Trandolaprilat [WHO-DD]

Common Name

English

TRANDOLAPRIL DIACID [MI]

Common Name

English

TRANDOLAPRIL RELATED COMPOUND E

Common Name

English

TRANDOLAPRIL RELATED COMPOUND E [USP-RS]

Common Name

English

TRANDOLAPRILATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247